Pinkerton JV - Search Results

1

Cardiovascular, cerebrovascular, and hepatic safety of desvenlafaxine for 1 year in women with vasomotor symptoms associated with menopause.

Archer DF, Pinkerton JV, Guico-Pabia CJ, Hwang E, Cheng RF; Study 3353 Investigators. Archer DF, et al. Among authors: pinkerton jv. Menopause. 2013 Jan;20(1):47-56. doi: 10.1097/gme.0b013e3182775fe9. Menopause. 2013. PMID: 23266840 Clinical Trial.

2

The North American Menopause Society recommendations for clinical care of midlife women.

Shifren JL, Gass ML; NAMS Recommendations for Clinical Care of Midlife Women Working Group. Shifren JL, et al. Menopause. 2014 Oct;21(10):1038-62. doi: 10.1097/GME.0000000000000319. Menopause. 2014. PMID: 25225714 No abstract available.

3

Elinzanetant for the Treatment of Vasomotor Symptoms Associated With Menopause: OASIS 1 and 2 Randomized Clinical Trials.

Pinkerton JV, Simon JA, Joffe H, Maki PM, Nappi RE, Panay N, Soares CN, Thurston RC, Caetano C, Haberland C, Haseli Mashhadi N, Krahn U, Mellinger U, Parke S, Seitz C, Zuurman L. Pinkerton JV, et al. JAMA. 2024 Aug 22;332(16):1343-54. doi: 10.1001/jama.2024.14618. Online ahead of print. JAMA. 2024. PMID: 39172446

4

Female Sexual Arousal Disorder: Sildenafil Cream as Potential Treatment in Development.

Pinkerton JV. Pinkerton JV. Obstet Gynecol. 2024 Aug 1;144(2):142-143. doi: 10.1097/AOG.0000000000005651. Obstet Gynecol. 2024. PMID: 39024608 No abstract available.

5

Design of OASIS 1 and 2: phase 3 clinical trials assessing the efficacy and safety of elinzanetant for the treatment of vasomotor symptoms associated with menopause.

Pinkerton JV, Simon J, Panay N, Seitz C, Parke S, Caetano C, Mellinger U, Haseli Mashhadi N, Haberland C, Atanackovic G, Holz C, Mao G, Morrison M, Nisius S, Schaefers M, Zuurman L. Pinkerton JV, et al. Menopause. 2024 Jun 1;31(6):522-529. doi: 10.1097/GME.0000000000002350. Epub 2024 Apr 3. Menopause. 2024. PMID: 38564691 Clinical Trial.

6

Hormonal Medications for Genitourinary Syndrome of Menopause.

Pinkerton JV, Vaughan MH, Kaunitz AM. Pinkerton JV, et al. Clin Obstet Gynecol. 2024 Mar 1;67(1):68-78. doi: 10.1097/GRF.0000000000000835. Epub 2023 Nov 21. Clin Obstet Gynecol. 2024. PMID: 38032827

7

Neurokinin Receptor Antagonist, Fezolinetant, for Treatment of Menopausal Vasomotor Symptoms.

Pinkerton JV, Redick DL, Homewood LN, Kaunitz AM. Pinkerton JV, et al. J Clin Endocrinol Metab. 2023 Oct 18;108(11):e1448-e1449. doi: 10.1210/clinem/dgad209. J Clin Endocrinol Metab. 2023. PMID: 37097747 Free PMC article. No abstract available.

8

Reassuring data regarding the use of hormone therapy at menopause and risk of breast cancer.

Pinkerton JV, Wilson CS, Kaunitz AM. Pinkerton JV, et al. Menopause. 2022 Sep 1;29(9):1001-1004. doi: 10.1097/GME.0000000000002057. Epub 2022 Aug 23. Menopause. 2022. PMID: 35998670 No abstract available.

9

Multidisciplinary Management of Menopause: Symposium Proceedings.

Kornstein SG, Pinkerton JV, Pace DT, Singer AJ, Kingsberg SA, Ellis LE, Ashley P, Klein W. Kornstein SG, et al. Among authors: pinkerton jv. J Womens Health (Larchmt). 2022 Aug;31(8):1071-1078. doi: 10.1089/jwh.2022.0175. J Womens Health (Larchmt). 2022. PMID: 35980244

10

The 2022 hormone therapy position statement of The North American Menopause Society.

“The 2022 Hormone Therapy Position Statement of The North American Menopause Society” Advisory Panel. “The 2022 Hormone Therapy Position Statement of The North American Menopause Society” Advisory Panel. Menopause. 2022 Jul 1;29(7):767-794. doi: 10.1097/GME.0000000000002028. Menopause. 2022. PMID: 35797481

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

155 results

Search Page

Filters